These observations not only demonstrate the potential value of newly developed BBB‐penetrable oral IGF1R inhibitors in GBM treatment, but also substantiate our above conclusion that tumor OPCs are preferentially susceptible to IGF1R targeting. Here, IGF1R is linked to neoplasm.